African Vaccine Regulatory Forum (AVAREF)

QUALITY ASSESSMENT

Study Full Title	
Short Title	
Protocol No.	
Version No.	
Study Drug	
Date of review	
Name of reviewers	

1.1. Introduction

Note

Scientific advice

1.2. GMP compliance

Information about all manufacturers involved (Drug Substance, Drug Product, placebo etc) and evidence of GMP (manufacturing licenses/ GMP certs, QP declarations provided):

Note

Name and address of site *(can be cut and paste from IMPD)*	**Function *(include reference to PRx, PLx etc as relevant)***	**Confirmation of valid license/ QP declaration *(tick if provided or comment if unavailable/ not required)***	
		☐	
		☐	
		☐	
		☐	

1.3. Assessment of the IMPD[1] (PR1, PR2 etc, replicate section 3 as required)

Delete non-relevant sections of text as required, but not headings

Registered, non-modified product only SmPC has been provided, IMPD(in this case section 3.3 is not required) ***Note***	☐
Assessment of the IMPD is included in section 3.3	☐

3.3 S Drug substance

The Drug substance:		
Has a monograph in	Ph. Eur. ☐ a Pharmacopoeia of an EU MS ☐ USP/JP ☐	No ☐
Has a valid CEP Yes ☐ No ☐	If yes: CEP no: Holder: special tests/limits, re-test period, TSE information, if relevant, should be indicated: ***Note***	
Is the active substance of an authorised drug product in the EU? Yes ☐ No ☐		
None of the above (full S Section is needed):		

S.1 General Information

S.1.1 Nomenclature

Note

Assessor's comment:

S.1.2 Structure

Does the submitted documentation cover this subsection adequately? Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

S.1.3 General Properties

Does the submitted material cover this subsection adequately?	Yes ☐ No ☐ NA ☐

Note a

Note b

Assessor's comment:

S.2 Manufacture

S.2.1 Manufacturer(s)

Substance: Sites declared	Yes ☐ No ☐ NA ☐

Assessor's comment: *See section 3.2 GMP Compliance above*

S.2.2 Description of Manufacturing Process and Process Controls

Substance: Manufacturing process and its controls are adequately described	Yes ☐ No ☐ NA ☐

Note a

Note b

Assessor's comment:

S.2.3 Control of Materials

Control of materials is adequately described	Yes ☐ No ☐ NA ☐

Note a

Note b

Note c

Assessor's comment:

S.2.4 Control of Critical Steps and Intermediates

Control of critical steps and intermediates is adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

S.2.5 Process Validation and/or Evaluation

Process validation is adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

S.2.6. Manufacturing Process Development

Manufacturing process development is adequately described	Yes ☐ No ☐ NA ☐

Note

Assessor's comment: *For biological IMPs: Comment on comparability data, if relevant.*

S.3 Characterisation

S.3.1 Elucidation of Structure and other Characteristics

Substance is sufficiently characterised	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

S.3.2 Impurities

Impurities are sufficiently characterised	Yes ☐ No ☐ NA ☐

Note a

Note b

Assessor's comment:

S.4 Control of Drug Substance

S.4.1 Specification(s)

An adequate drug substance specification, including appropriate limits, has been proposed.	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

S.4.2 Analytical Procedures

The analytical methods have been adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

S.4.3 Validation of Analytical Procedures

For phase I trials suitability of methods commensurate with stage of development has been confirmed; acceptance limits and parameters for performing validation of the analytical methods are presented For phase II/III trials, suitability of methods commensurate with stage of development has been demonstrated and a summary of validation results is provided	Yes ☐ No ☐ NA ☐ Yes ☐ No ☐ NA ☐

Assessor's comment:

S.4.4 Batch Analyses

Representative batch analyses data provided for all the relevant manufacturing process and for each drug substance manufacturer	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

S.4.5 Justification of Specification(s)

Justification of specifications is acceptable	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

S.5 Reference Standards or Materials

Reference Standard: A suitable reference standard is adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

S.6 Container Closure System

Substance container is adequately characterised and suitable for the drug substance.	Yes ☐ No ☐ NA ☐

Assessor's comment:

S.7 Stability

Substance stability is satisfactory and adequately described for all relevant manufacturing processes	Yes ☐ No ☐ NA ☐

List proposed shelf-life/retest period and storage conditions of DS.

Summary of stability studies provided in support of the proposed shelf-life (delete/amend columns as appropriate). State number of months for which data is available.

Batch details (e.g. batch number)	**Manufacturing process**	**-70ºC**	**-20ºC**	**5 °C**
	25°C / 60 % RH			
	30°C / 65 % RH			
	40°C / 75 % RH			

Comment on whether trends or OOS results observed.

Extension of shelf-life will be made without substantial amendment: Yes ☐ No ☐ NA ☐

If yes, extension to be made in accordance with a registered protocol: Yes ☐ No ☐ NA ☐

Assessor's comment:

3.3. P Drug Product name of IMP (repeat section for additional IMPs)

P.1 Description and Composition of the Investigational Medicinal Product

Drug product: Description and composition is adequate.	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

P.2 Pharmaceutical Development

Drug product: Pharmaceutical development is adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.3 Manufacture

P.3.1 Manufacturer(s)

Drug Product: Sites declared	Yes ☐ No ☐ NA ☐

Assessor's comment:

See section 3.2 GMP Compliance above.

P.3.2 Batch Formula

Drug product: batch formula is adequately described	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

P.3.3 Description of Manufacturing Process and Process Controls

Drug product: Manufacturing process and process control are adequately described	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

P.3.4 Controls of Critical Steps and Intermediates

Drug product: Controls of Critical Steps and Intermediates are adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.3.5 Process Validation and/or Evaluation

Process validation is adequately described	Yes ☐ No ☐ NA☐

Note

Assessor's comment:

P.4 Control of Excipients

Note

P.4.1 Specifications

For excipients not described in current pharmacopoeias adequate specifications and acceptance criteria have been provided	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.4.2 Analytical Procedures

Analytical procedures are adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.4.3 Validation of the Analytical Procedures

Analytical procedures are adequately validated	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.4.4 Justification of Specifications

An adequate justification for excipients specification and limits is described	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

P.4.5 Excipients of Animal or Human Origin

The IMP contains excipients of animal origin	Yes ☐ No ☐ NA ☐
TSE Safety Confirmation provided	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.4.6 Novel Excipients

Drug product: Excipients are adequately controlled	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

P.5 Control of Drug Product

P.5.1 Specifications

Drug product: An adequate drug product specification, including appropriate limits, is described	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

P.5.2 Analytical Procedures

The analytical methods have been adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.5.3 Validation of Analytical Procedures

For phase I trials suitability of methods commensurate with stage of development has been confirmed; acceptance limits and parameters for performing validation of the analytical methods are presented	Yes ☐ No ☐ NA ☐
For phase II/III trials, suitability of methods commensurate with stage of development has been demonstrated and a summary of validation results is provided	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.5.4 Batch Analyses

Representative batch analyses provided for each drug product manufacturer and its link to manufacturing processes (if relevant)	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.5.5 Characterisation of Impurities

Drug product impurity information provided is acceptable	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

P.5.6 Justification of Specification(s)

Drug product: An adequate justification for drug product specification and limits is described	Yes ☐ No ☐ NA ☐

Assessor's comment:

P.6 Reference Standards or Materials

Reference Standard: A suitable reference standard is adequately described	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

P.7 Container Closure System

Product container is adequately characterised and suited for the IMP Yes ☐ No ☐ NA ☐

Assessor's comment:

P.8 Stability

P.8.1 Stability Summary and Conclusion

P.8.2 Post-approval Stability Protocol and Stability Commitment

P.8.3 Stability Data

Drug product has been adequately tested regarding stability Yes ☐ No ☐ NA ☐

What is proposed shelf-life and storage condition of IMP?

Summary of stability studies provided in support of the proposed shelf-life (delete/amend columns as appropriate). State the number of months for which data are available.

Batch details (e.g. batch number)	Manufacturing process	-70ºC	-20ºC	5 °C	25°C / 60% RH	30°C / 65% RH	40°C / 75% RH

Comment whether trends or OOS results observed.

Extension of shelf-life will be made without substantial amendment: Yes ☐ No ☐ NA ☐

If yes, extension to be made in accordance with a registered protocol: Yes ☐ No ☐ NA ☐

Assessor's comment:

3.3 A Appendices

A.1 Facilities and Equipment

Not applicable

A.2 Adventitious Agents Safety Evaluation

Safety related to adventitious agents is adequate	Yes ☐ No ☐ NA ☐

Note: If not applicable, text below can be deleted:

Summarise acceptability of information provided on:

TSE agents

- Short description or list of materials from TSE-risk species. Demonstration of compliance with Ph. Eur 5.2.8 (relevant EDQM TSE-Certificate or adequate documentation).

Viral safety

-Identification of materials of biological origin: (e.g. Cell substrates, blood/tissue donations) reagents (e. g. cell culture media blood), as well as excipients.

-Testing of source materials: Summarise the testing regime. Is the testing regime appropriate and adequate?

-Testing of unpurified bulk: Is the strategy for routine testing adequate?

-Viral clearance studies: Is the study design according to relevant guidelines.

-Summary of the viral clearance studies (model viruses used, viral clearance steps, total theoretical viral load).

Other adventitious agents

Assessor's comment:

A.3 Novel Excipients

Information on novel excipients has been provided in line with the respective clinical phase	Yes ☐ No ☐ NA ☐

Note a

Note b

Assessor's comment:

A.4 Solvents for Reconstitution/Dilution

Information on solvents has been provided	Yes ☐ No ☐ NA ☐

Note

Assessor's comment: ***Note***

1.4. Comparator (Comparator 1, comparator 2 etc – individual sections of the assessment form (3.S and 3.P) for IMPs to be replicated as required)

The data provided for the comparator is acceptable	Yes ☐ No ☐ NA ☐

Note

Assessor's comment:

1.5. Placebo (PL1, PL2 etc, - section to be replicated as required)

Placebo: information provided is acceptable *Or (delete if not applicable):* No information has been provided, but this is acceptable as product has the same composition as the IMP, is manufactured by the same manufacturer and is not sterile	Yes ☐ No ☐ NA ☐

Note

Summary of information provided and its acceptability:

P.1 Description and composition

P.2 Pharmaceutical Development

P.3 Manufacture

P.4 Control of Excipients

P.5 Control of Placebo Product

P.6 Container closure system

P.7 Stability

Assessor's comment:

1.6. Auxiliary medicinal products– individual sections of the assessment form (3.S and 3.P) for IMPs to be replicated as required

The quality data provided for non authorised auxiliary medicinal products are acceptable	Yes ☐ No ☐ NA ☐

Note

3.S

3.P

Assessor's comment:

1.7. Additional considerations for ATMPs or combined products (involving devices)

Additional information has been provided	Yes ☐ No ☐ NA ☐

Note

Summarise information provided including:

- *Adequate description of transport to clinical trial site*
- *Adequate description of storage at clinical trial site*

Adequate description of reconstitution of ATMP.

Assessor's comment:

1.8. Labelling

Are the proposed labeling in line with ANNEX VI of the Regulation	Yes ☐ No ☐ NA ☐

Assessor's comment: ***Note***

1.9. Blinding

Assessor's comment: ***Note***

1.10. Assessor's Overall Conclusions on the Quality Part

The quality data are acceptable	☐
Supplementary information needs to be provided (refer to the requests for additional information)	☐
Overall comment/ conclusion on the quality assessment:	

1.10.1. REQUESTS FOR ADDITIONAL INFORMATION: QUALITY (see also Section 9):